About Kyle Lefkoff
Form D filings for Ambrosia Biosciences in 2024 list Kyle Lefkoff as director.
Kyle Lefkoff reports to the SEC as a director or major shareholder of 4 public companies, including Array Biopharma (ARRY), Viridian Therapeutics (VRDN) and Rally Software Development (RALY).
Kyle Lefkoff first appears on SEC filings in 2006.
Experience
This experience comes from SEC filings. The years are when the filings name Kyle Lefkoff in the role, so the role may have started earlier or lasted longer.
AI
Array Biopharma Inc.
Director
2006 – 2019 · Public company (ARRY)
VI
Viridian Therapeutics, Inc.
Director
2017 · Public company (VRDN)
RC
Rally Software Development Corp
10% owner
2013 · Public company (RALY)
OI
Oruka Therapeutics, Inc.
10% owner
2009 · Public company (ORKA)
Key Colleagues at Startups
The people Kyle Lefkoff works with at each company, as listed on that company's latest Form D.
Ambrosia Biosciences Inc. · Form D/A, Aug 20, 2024
DS
David Snitman
Director
WM
William Marshall
Director
NT
Nicholas Traggis
Executive officer and director
JO
John Orwin
Director